Skip to main content
OpenTrials
Completed

NCT Number: NCT03262675

NAtional TUnisian REgistry of Heart Failure

NATURE-HF is an observational, multicentric and longitudinal study of heart failure performed with 100 tunisian cardiologists.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Société Tunisienne de Cardiologie & de Chirurgie Cardio-Vasculaire

Tunis, Tunisie, 1000, Tunisia

About this study

The NATURE-HF is a national clinical non-interventional registry of heart failure, carried out in Tunisia at cardiology departments in hospitals and in liberal cardiology consultations. 100 cardiologists participate in the enrollment of the eligible patients as investigators. A Committee of Experts validates the protocol methodology and supervises the data-management. A Steering Committee helps investigators to monitor their patient inclusions, performs audit trails and prepares the statistical analysis plan for the study.

Collected data are managed by the DACIMA Clinical Suite®, the electronic data capture platform which complies with the FDA 21 CFR part 11 requirements (Food and Drug Administration 21 Code of Federal Regulations part 11), the HIPAA specifications (Health Insurance Portability and Accountability Act), and the ICH standards (International Conference on Harmonisation).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with chronic heart failure
  • Patient with acute heart failure (new onset or not)
  • The diagnosis of heart failure is at the discretion of the investigator
  • Informed and signed consent

Exclusion criteria

  • Life expectancy <12 months for extra cardiac disease
  • Isolated Right Heart Failure
  • Pregnant woman
  • Renal failure with creatinine clearance < 15 ml / min
  • Hemodialysis patients
  • Cardiac surgery planned within 3 months
  • Congenital heart disease

Treatment and study plan

Primary outcomes

  1. Cardiovascular death

    Time frame: Time-To-Event measure up to 12 months from baseline

    Incidence of cardiovascular death including sudden death, death from refractory heart failure and death from stroke

Secondary outcomes

  1. Heart Failure Readmission

    Time frame: At 1, 3 and 12 months from patient enrollment

    Incidence of heart failure readmissions

  2. Global Death

    Time frame: Time-To-Event measure up to 12 months from baseline

    Incidence of death of all causes (cardiovascular death and non-cardiovascular death)

Sponsors and collaborators

Lead sponsor

Dacima Consulting

Other

Collaborators

  • Société Tunisienne de Cardiologie & de Chirurgie Cardio-Vasculaire

Registry information

Acronym: NATURE-HF

Important dates

Study start
2017
Primary completion
2017
Study completion
2019
First posted
Aug 25, 2017
Registry last updated
Jan 22, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.